Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Oral Proteolytic Enzyme Combinations (Trypsin, Chymotrypsin, Papain, Bromelain)
Combinations of protein-cleaving enzymes (trypsin, chymotrypsin, papain, bromelain), often with rutoside, taken between meals for joint pain and swelling. In osteoarthritis they were non-inferior to diclofenac in two 6-week trials designed to test that, and a pooled reanalysis reported fewer adverse events than diclofenac, but placebo-controlled evidence is mixed and a 721-person ankle sprain trial found no benefit.
What the evidence says
Oral Proteolytic Enzymes doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1969–2026 with a typical study size of 138 participants.
Based on 38 studies · 2 meta-analyses · 31 RCTs · 6,438 total participants
Study base
38 studies indexedBy outcome
Every outcome below: Too few graded studies.
Emerging 4.5. In knee and hip osteoarthritis, oral enzyme combinations (bromelain, trypsin and rutoside where the abstract names the contents) were non-inferior to diclofenac in two 6-week randomised trials, and a pooled reanalysis of six knee trials (774 patients), which includes the knee non-inferiority trial and the 150-person placebo-arm trial, found the enzymes non-inferior to diclofenac on the Lequesne index (mean difference 0.31 points, 95% CI -0.10 to 0.73) against a pre-set margin of 3 points, about as large as the 3.5-point improvement seen in each arm, with fewer adverse events, but most of those trials had no placebo arm. Placebo-controlled evidence is mixed. A 150-person knee trial beat placebo on its primary outcome and not on WOMAC, a placebo-controlled crossover improved two KOOS subscales but not the overall score, and a 638-person trial in recurrent cystitis found half the recurrence rate with the enzymes added to an antibiotic. Against that, the largest musculoskeletal trial (721 people with ankle sprain) found no benefit, a marathon trial found no anti-inflammatory effect, a radiotherapy mucositis trial was null with earlier onset of mucositis on enzymes, a 2021 systematic review of 15 oncology studies found no clear benefit, and a 2003 systematic review judged the anti-inflammatory trials methodologically deficient. The cystitis trial does not raise the score: it is a single Russian-language report in an indication no goal here covers, with the abstract not stating funding or the enzyme dose, and it is offset by a null randomised trial and a null systematic review. Several positive trials have manufacturer sponsorship or staff authors.
27 randomised trials
92% were about Oral Proteolytic Enzymes in an audit of 12 of them
Every randomised or controlled trial of Oral Proteolytic Enzymes indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Oct 2026
51 trials ongoing or recruiting · 92 completed on ClinicalTrials.gov
20 of the completed trials have posted results
Registered trials show research momentum for Oral Proteolytic Enzymes, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Oral proteolytic enzyme combinations, sold as "systemic enzymes", pair animal pancreatic enzymes (trypsin, chymotrypsin) with plant enzymes (bromelain from pineapple, papain from papaya), often with the flavonoid rutoside.
Taken between meals, they are proposed to reduce inflammation and swelling after part of the dose is absorbed and binds the blood protein alpha-2-macroglobulin, though how much reaches the circulation is debated. In Germany several enzyme preparations are registered as anti-inflammatory medicines.
The best-studied combination is bromelain, trypsin and rutoside.
In knee osteoarthritis that combination was non-inferior to diclofenac over 6 weeks in a randomised trial of 103 people, a hip trial of an oral enzyme combination found the same over 6 weeks, and a pooled reanalysis of six knee trials (774 patients) of an oral enzyme combination, including the 103-person knee trial and the 150-person knee trial described here, found the enzymes non-inferior to diclofenac on the Lequesne index (mean difference 0.31 points, 95% CI -0.10 to 0.73) against a pre-set margin of 3 points, about as large as the 3.5-point improvement seen in each arm, with fewer adverse events than diclofenac.
Because the pooled set includes those two trials, it is not additional evidence on top of them. Non-inferiority is not superiority, though, and most of those trials had no placebo arm.
A 12-week knee trial of an oral enzyme combination in 150 adults, with both placebo and diclofenac arms, beat placebo on its primary outcome but not on WOMAC, and found no difference between the enzyme and diclofenac groups without testing for non-inferiority.
A placebo-controlled crossover trial of bromelain, trypsin and rutoside in 45 people with knee osteoarthritis improved two KOOS subscales but not the overall score. After hip replacement a small trial found lower CRP and pain.
In a 638-person placebo-controlled trial in women with recurrent cystitis, adding an oral enzyme combination to a single antibiotic course roughly halved recurrences (12.6% versus 24.5%).
Against that, the largest trial, 721 people with an ankle sprain, found no benefit over placebo, a marathon trial found no effect on inflammation, a 301-person multiple sclerosis trial was null, a placebo-controlled trial of a papain, trypsin and chymotrypsin tablet during head-and-neck radiotherapy found no benefit for mouth ulceration, a 2021 systematic review of 15 oncology studies found no clear benefit, and a 2003 systematic review judged the anti-inflammatory trials methodologically deficient.
Several positive trials were sponsored by, or have authors employed by, the manufacturer. Bromelain and serrapeptase taken on their own have separate pages.
Trypsin, chymotrypsin, papain and bromelain break down proteins. Taken between meals, a small fraction is thought to be absorbed and carried in the blood bound to alpha-2-macroglobulin, though how much reaches the circulation is debated.
In a placebo-controlled crossover trial in knee osteoarthritis the combination raised alpha-2-macroglobulin and the anti-inflammatory cytokine IL-10 and lowered a urinary marker of cartilage breakdown.
Proposed to reduce swelling by breaking down fibrin and inflammatory proteins in injured tissue. Swelling results in trials are inconsistent, and a large ankle sprain trial found no effect.
Many combinations add rutoside (rutin), a flavonoid proposed to reduce capillary leakage. Rutin has its own page.
Avoid. Not studied in pregnancy, product composition varies, and components such as bromelain can affect blood clotting. This is a precaution, not evidence of harm to the baby.
Not studied. Use only if a clinician advises it.
Use only with the prescriber's agreement and bleeding monitoring.
Head-to-head trials found it non-inferior to diclofenac over the short term, with fewer adverse events in a pooled reanalysis, but discuss any switch with a clinician. Effects beyond 12 weeks are not studied.
Tell the surgical team about this product well in advance and follow their instructions on stopping it. One small hip-replacement trial gave it before surgery and reported no harmful effects on haemorheology, the flow properties of blood. That does not show it is safe before surgery in general.
May increase bleeding risk alongside anticoagulant or antiplatelet drugs, mainly because of the bromelain in most blends. Clinical evidence for this blend is limited, and a marathon trial that found no change in clotting or platelet markers in healthy runners did not test this combination.
Older studies reported that bromelain raised blood levels of amoxicillin and tetracycline. Tell the prescriber if taking it during an antibiotic course.
The available source did not grade how severe these reactions were. This does not mean they were mild.
Tip: If you develop a new or unexpected symptom, pause this optional product and seek advice before trying a lower dose, a different schedule or an added remedy. Follow any urgent instructions for the symptom now.
Tip: Stop and seek care if rash, swelling or breathing difficulty occurs
Oral Proteolytic Enzymes has an evidence score of 4.5/10 — emerging evidence based on 38 indexed studies, including 1 meta-analysis. Combinations of protein-cleaving enzymes (trypsin, chymotrypsin, papain, bromelain), often with rutoside, taken between meals for joint pain and swelling. In osteoarthritis they were non-inferior to diclofenac in two 6-week trials designed to test that, and a pooled reanalysis reported fewer adverse events than diclofenac, but placebo-controlled evidence is mixed and a 721-person ankle sprain trial found no benefit. Representative study: PMID 27853388.
Dosing for Oral Proteolytic Enzymes: No portable dose: tablet counts do not transfer between blends, because products differ in which enzymes they contain and how much. Study examples, for one formulation only (each tablet bromelain 90 mg, trypsin 48 mg and rutoside 100 mg): 2 tablets three times a day for 7 days after surgery, and 3 tablets twice a day for 8 weeks in knee osteoarthritis. The highest amount cited for this formulation was bromelain 1,080 mg, trypsin 576 mg and rutoside 1,200 mg a day for 3 weeks in healthy runners. None of these is a maximum for papain, fungal enzyme or other blends, so follow the label for those.
The best time to take Oral Proteolytic Enzymes is between meals. It can be taken on an empty stomach. Systemic enzyme products are labelled to be taken between meals so the enzymes are not spent digesting food protein.
No consumer dose of Oral Proteolytic Enzymes is endorsed, so there is no dose at which it can be called safe. Talk to a healthcare provider before taking it. Reported side effects include allergic reaction (papain, bromelain or animal-derived enzymes), digestive upset. How often they occur is not established for all of them. Use caution if any of these apply to you: Allergy to pineapple, papaya or papain, or to animal-derived pancreatic enzymes (trypsin, chymotrypsin); Bleeding disorders; Upcoming surgery, unless the surgeon has agreed to its use.
Curcumin
HelpedTurmeric's active compound that modulates NF-kB inflammatory pathways — supports mood, joint health, and post-exercise recovery.
Omega-3
HelpedEssential fatty acids critical for brain health, mood regulation, and reducing inflammation throughout the body.
CoQ10
HelpedA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Collagen
Too few graded studiesHydrolyzed peptides that rebuild skin elasticity, reduce joint pain, and strengthen bone density — results build over 8-12 weeks.
Explore: Best supplements for Body HealthBest supplements for Athletic PerformanceBest supplements for Vitality & Longevity
Edited by Dr. Baher Al Hakim · Last updated November 2026 · evidence from 38 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.